Salah Najm, MD
Pulmonary Disease · Topeka, KSNPI 1982868097
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.0% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by GSK at 28.7% of the total. Reporting peaked in 2019 at $282 and has fallen 64.4% since, to $101 in 2025. That places this record below the midpoint for pulmonary disease clinicians in KS, where the typical reported total is $1,991.
Across 23 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$127
- Intuitive Surgical$101
- Genentech USA, Inc.$68
- Mylan Specialty L.p.$35
- Actelion Pharmaceuticals US, Inc.$29
- C. R. Bard, Inc. & Subsidiaries$24
- plus $59 from 4 others
Across 34 payments — averaging $3665.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$78K
- Sanofi US Services Inc.$47K
- Merck$108
What the payments were for
- Food & beverage$40391%
- Education$409%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 10 | $127 |
| Intuitive Surgical | 1 | $101 |
| Genentech USA, Inc. | 3 | $68 |
| Mylan Specialty L.p. | 2 | $35 |
| Actelion Pharmaceuticals US, Inc. | 2 | $29 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $24 |
| Advanced Respiratory, Inc | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Portola Pharmaceuticals, LLC | 1 | $13 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$443 in reported general payments places this provider in the 25th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 104 | $76,635 |
| Pirfenidone | 18 | $45,163 |
| NucalaMepolizumab | 12 | $44,140 |
| Breo ElliptaFluticasone/Vilanterol | 80 | $42,014 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 62 | $29,807 |
| Spiriva HandihalerTiotropium Bromide | 20 | $12,795 |
| Spiriva RespimatTiotropium Bromide | 15 | $9,459 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $7,840 |
| DuleraMometasone/Formoterol | 20 | $7,594 |
| Fluticasone Propionate HfaFluticasone Propionate | 13 | $7,325 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $6,703 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $6,617 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $4,813 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 124 | $4,091 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 25 | $2,776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $127 | $199,213273 claims |
| AstraZenecaSymbicort | $12 | $7,84020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Topeka
- Hassan TahaTopeka$7K
- Miguel Tsukayama OdaTopeka$6K
- Vimalkumar PatelTopeka$5K
- Abhishek ChakrabortiTopeka$4K
- Amanda GudgellTopeka$856
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
- Chase HallKansas City$329K
- Maykol Postigo JasahuiKansas City$322K
- Abdel-Ghanie Abu-SamraWichita$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.